IMAC (IMAC) Competitors $0.07 +0.01 (+13.33%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock IMAC vs. MYNZ, JBIO, NKGN, HCWB, LIAN, PRTG, GRAY, RKDA, EVOK, and STSSShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Mainz Biomed (MYNZ), Jade Biosciences (JBIO), NKGen Biotech (NKGN), HCW Biologics (HCWB), LianBio (LIAN), Portage Biotech (PRTG), Graybug Vision (GRAY), Arcadia Biosciences (RKDA), Evoke Pharma (EVOK), and Sharps Technology (STSS). These companies are all part of the "medical" sector. IMAC vs. Its Competitors Mainz Biomed Jade Biosciences NKGen Biotech HCW Biologics LianBio Portage Biotech Graybug Vision Arcadia Biosciences Evoke Pharma Sharps Technology Mainz Biomed (NASDAQ:MYNZ) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment. Do institutionals & insiders believe in MYNZ or IMAC? 24.3% of IMAC shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by insiders. Comparatively, 10.0% of IMAC shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher earnings & valuation, MYNZ or IMAC? IMAC has higher revenue and earnings than Mainz Biomed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMainz Biomed$893.99K5.12-$21.65M-$65.60-0.02IMAC$15.22M0.12-$10.54MN/AN/A Do analysts prefer MYNZ or IMAC? Mainz Biomed currently has a consensus target price of $14.00, indicating a potential upside of 952.63%. Given Mainz Biomed's stronger consensus rating and higher probable upside, equities analysts plainly believe Mainz Biomed is more favorable than IMAC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MYNZ or IMAC? In the previous week, IMAC had 5 more articles in the media than Mainz Biomed. MarketBeat recorded 6 mentions for IMAC and 1 mentions for Mainz Biomed. IMAC's average media sentiment score of 0.10 beat Mainz Biomed's score of 0.00 indicating that IMAC is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IMAC 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is MYNZ or IMAC more profitable? Mainz Biomed has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Mainz Biomed's return on equity of 0.00% beat IMAC's return on equity.Company Net Margins Return on Equity Return on Assets Mainz BiomedN/A N/A N/A IMAC -75.40%-52.17%-34.51% Which has more volatility & risk, MYNZ or IMAC? Mainz Biomed has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, IMAC has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500. SummaryMainz Biomed beats IMAC on 9 of the 14 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80M$1.30M$5.48B$9.54BDividend YieldN/AN/A4.73%4.09%P/E RatioN/AN/A28.8623.83Price / Sales0.120.12371.7266.14Price / CashN/AN/A35.4557.96Price / Book0.100.108.275.54Net Income-$10.54M-$10.54M$3.25B$259.28M7 Day PerformanceN/AN/A-3.73%-4.68%1 Month PerformanceN/AN/A4.29%4.36%1 Year PerformanceN/AN/A25.87%17.89% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$0.07+13.3%N/A-96.7%$1.80M$15.22M0.00106News CoverageMYNZMainz Biomed2.6315 of 5 stars$1.85-5.8%$14.00+658.0%-91.9%$6.35M$890K-0.0330News CoveragePositive NewsJBIOJade Biosciences1.8402 of 5 stars$7.55-2.6%$15.00+98.7%N/A$6.34MN/A-0.1320NKGNNKGen Biotech0.3549 of 5 stars$0.14-26.3%N/A-86.9%$6.29MN/A-0.03N/AShort Interest ↑HCWBHCW Biologics2.6849 of 5 stars$4.34+4.5%$35.00+707.4%-84.3%$6.24M$2.57M-0.1940Positive NewsGap UpLIANLianBioN/A$0.06+18.3%N/A-82.5%$6.16MN/A-0.07110PRTGPortage BiotechN/A$5.72-4.0%N/A+52.4%$6MN/A-0.146GRAYGraybug VisionN/A$3.80+3.0%N/A-23.2%$5.97MN/A-2.2027High Trading VolumeRKDAArcadia Biosciences2.1242 of 5 stars$4.33-1.0%$6.00+38.7%+43.2%$5.93M$5.05M-1.0160EVOKEvoke Pharma0.2678 of 5 stars$3.97-9.0%N/A-3.5%$5.91M$10.25M-1.384Short Interest ↑STSSSharps Technology0.8277 of 5 stars$5.77-4.4%N/AN/A$5.88MN/A0.003Gap Down Related Companies and Tools Related Companies Mainz Biomed Competitors Jade Biosciences Competitors NKGen Biotech Competitors HCW Biologics Competitors LianBio Competitors Portage Biotech Competitors Graybug Vision Competitors Arcadia Biosciences Competitors Evoke Pharma Competitors Sharps Technology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
